Norovirus is surging across the U.S., with case numbers higher now than they've been at the same time in more than ... pathogens and bacterial vaccines at Moderna. So any vaccine would have ...
Moderna has reported ... compared to one month post booster," she commented. "These data tend to support the conclusion that the time has come to use variant vaccines to boost response among ...
Additionally, people’s immunity to particular strains of norovirus wane over time ... vaccines with similar technology show that antibodies can migrate: For instance, with Moderna’s Covid ...
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.